Trial Profile
A Multi-center, Open-label, Non-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of TMX-67 after Oral Adminisitration in Hyperuricemic Pediatric Patients with or without Gout
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary)
- Indications Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Teijin Pharma
- 23 Oct 2018 New trial record